Navigation Links
Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire/ -- Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

The name ViaCyte retains the Company's identity as a leading cell therapy company, as "–cyte" is derived from the Greek "kytos," which means cell.  As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important.  With its new name, the Company has also adopted a new corporate logo.  An abstract flower emphasizes the rejuvenation possible through a stem cell-derived therapy.

The name ViaCyte was previously used by ViaCell, Inc., but their use was discontinued following acquisition of ViaCell by Perkin Elmer, Inc.  The Company has acquired all rights to the ViaCyte service marks and internet domain name addresses previously owned by ViaCell.  The Company's product developments are not related to those of ViaCell or Perkin Elmer.

The Company's new name also provides consolidation.  The Company is the result of a three-way merger in 2004 of Novocell, Inc. (Irvine, CA), CyThera, Inc. (San Diego, CA) and BresaGen, Inc. (Athens, GA).  Going forward, the Company is focused on stem cell innovations initiated in its San Diego and Athens locations, and has discontinued work on PEG-encapsulated islets that were the focus of its former Irvine location.  All of the Company's operations will use the ViaCyte name.  The Company's wholly owned subsidiary in Athens, Georgia will take the name ViaCyte Georgia.

About ViaCyte, Inc.

ViaCyte is a preclinical therapeutic company focused on diabetes.  Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
2. Missouri Becomes the Fourth State to Connect to Kentuckys Real-time Cold Medicine Tracking System
3. Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System
4. US Oncology Foundation Becomes Life Beyond Cancer Foundation
5. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
6. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
7. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
8. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
9. Merieux Alliance Becomes Institut Merieux
10. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
11. Triage Wireless, Inc. Becomes Sotera Wireless, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):